Suppliers and packagers for tonmya

tonmya

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Tonix	TONMYA	cyclobenzaprine hydrochloride	TABLET;SUBLINGUAL	219428	NDA	Tonix Medicines, Inc.	70792-102-14	14 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (70792-102-14)	2025-08-15
Tonix	TONMYA	cyclobenzaprine hydrochloride	TABLET;SUBLINGUAL	219428	NDA	Tonix Medicines, Inc.	70792-102-30	30 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (70792-102-30)	2025-08-15
Tonix	TONMYA	cyclobenzaprine hydrochloride	TABLET;SUBLINGUAL	219428	NDA	Tonix Medicines, Inc.	70792-102-60	60 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (70792-102-60)	2025-08-15
Tonix	TONMYA	cyclobenzaprine hydrochloride	TABLET;SUBLINGUAL	219428	NDA	Tonix Medicines, Inc.	70792-102-90	90 TABLET, ORALLY DISINTEGRATING in 1 BOTTLE (70792-102-90)	2025-08-15

Suppliers for the Pharmaceutical Drug: TONMYA

Last updated: October 8, 2025

Introduction

TONMYA is the registered trademark of a pharmaceutical product containing the active ingredient topiramate, used primarily for the treatment of epilepsy, migraine prophylaxis, and off-label indications such as weight management. As with many specialized pharmaceuticals, sourcing reliable suppliers for TONMYA—whether for manufacturing, distribution, or procurement—is vital for stakeholders aiming to ensure quality, compliance, and supply chain resilience. This article explores the landscape of suppliers associated with TONMYA, including licensed manufacturers, authorized distributors, and potential sourcing factors that influence procurement decisions.

Regulatory and Patent Landscape

Understanding the supplier ecosystem for TONMYA necessitates an appreciation of its regulatory status. Topiramate, the active pharmaceutical ingredient (API), was first approved by the U.S. Food and Drug Administration (FDA) in 1996. The original patent for the drug has since expired, leading to numerous generic manufacturing entities worldwide. As a result, a broad spectrum of suppliers now manufactures and supplies topiramate formulations, including TONMYA.

Key regulatory agencies—such as the FDA, the European Medicines Agency (EMA), and the Pharmaceuticals and Poisons Board in various jurisdictions—approve and oversee manufacturing quality. Suppliers must obtain Good Manufacturing Practice (GMP) certification to export or sell pharmaceutical products internationally, which influences global sourcing options.

Manufacturers of Topiramate (Active Ingredient)

The primary suppliers for TONMYA often originate from companies manufacturing the API—topiramate—either directly or through authorized manufacturing partnerships. These companies typically operate under licensed agreements with patent holders or generic firms that produce finished formulations tailored for the market.

Leading API Suppliers

• Mitsubishi Tanabe Pharma Corporation: As the original patent holder, Mitsubishi developed and licensed the drug. While patent protection has expired, Mitsubishi continues to be involved in certain markets through licensing or distribution agreements.

• Teva Pharmaceutical Industries Ltd.: A dominant generic manufacturer, Teva produces topiramate API under strict quality controls, supplying to various finished formulation manufacturers globally.

• Siegfried AG: This Swiss-based contract manufacturer supplies active pharmaceutical ingredients, including topiramate, to multiple finished drug producers worldwide.

• Hetero Drugs Ltd.: An India-based generic pharmaceutical company with GMP-certified facilities, supplying topiramate API to global markets.

• Aurobindo Pharma: Another major Indian pharmaceutical enterprise producing API for numerous generics, including topiramate, with a growing international footprint.

Finished Dosage Form Suppliers

Finished formulations of TONMYA are supplied by licensed pharmaceutical companies licensed to produce the brand or its generics, including:

• Mylan (now part of Viatris): Historically supplied generic topiramate formulations in various markets.

• Sun Pharmaceutical Industries Ltd.: Manufactures and distributes topiramate-based medications across multiple regions.

• Dr. Reddy’s Laboratories: Offers generic topiramate formulations with appropriate regulatory approvals.

• Amneal Pharmaceuticals: Produces generic topiramate tablets for several markets.

• Zydus Cadila: An Indian pharmaceutical company providing topiramate formulations globally.

Most of these enterprises possess the requisite GMP certification and production licenses, ensuring compliance with international quality standards.

Authorized Distributors and Supply Chain Considerations

In addition to manufacturing entities, a network of authorized distributors plays a critical role in the supply chain for TONMYA. These entities often operate under licensing agreements with pharmaceutical companies and are responsible for local/regional distribution.

• Global pharmaceutical distributors such as McKesson, Cardinal Health, and Medipal Holdings are key players in distributing TONMYA within specific territories.

• Regional distributors often operate under licensing agreements with regional manufacturers or importers, strictly adhering to local regulatory frameworks.

Supply chain integrity hinges on choosing suppliers with proven compliance records, robust quality assurance processes, and traceability of products. Recent trends emphasize serialization and electronic track-and-trace systems to prevent falsified medicines, especially in high-stakes markets.

Emerging and Alternative Suppliers

In conjunction with traditional manufacturing giants, emerging manufacturers in India, China, and Eastern Europe offer APIs and finished formulations that may be compliant with regional regulations but vary in quality management standards. Stakeholders must undertake rigorous supplier qualification processes, including audits, GMP certification verification, and quality testing to assess reliability.

Supply Challenges and Risk Factors

Recent disruptions—caused by geopolitical issues, pandemic-related manufacturing constraints, and raw material shortages—have affected the supply of TONMYA and similar pharmaceuticals. Diversifying sourcing strategies and establishing strong relationships with multiple suppliers mitigate risks.

Furthermore, patent expirations have led to increased competition among generic manufacturers, which, while beneficial in reducing costs, requires rigorous due diligence to ensure product quality and regulatory compliance.

Legal and Compliance Considerations

Procurement strategies must include compliance with regional pharmaceutical regulations, registration requirements, and import-export controls. Only approved suppliers with verified Good Manufacturing Practice (GMP) certifications should be considered, supported by certification documents, batch records, and certificates of analysis (COA).

Conclusion

The supply landscape for TONMYA is dynamic, driven by the availability of topiramate APIs from established players such as Teva, Mitsubishi, and Indian generics firms. Larger multinational pharmaceutical companies and regional distributors form a resilient supply network, but recent supply chain disruptions underscore the importance of robust supplier qualification processes. Ensuring high-quality, compliant sourcing is critical for healthcare providers, distributors, and regulatory authorities to maintain uninterrupted access to this essential medication.

---

Key Takeaways

• Several reputable manufacturers, including Teva, Mitsubishi, and Indian generics firms such as Aurobindo and Hetero, supply topiramate APIs and finished formulations for TONMYA.
• Patent expirations have expanded the global supplier base, increasing competition but necessitating rigorous quality assurance.
• Supply chain resilience depends on diversification, verified GMP compliance, and rigorous supplier qualification.
• Strategic procurement should prioritize product traceability, certification, and adherence to regional regulatory standards.
• The evolving regulatory landscape emphasizes serialization and supply chain transparency to prevent counterfeit issues.

---

FAQs

1. Who Are the Main Suppliers of TONMYA in the Global Market?

Major suppliers include Teva Pharmaceutical Industries, Mitsubishi Tanabe Pharma, and Indian generic manufacturers like Aurobindo Pharma, Hetero Drugs, and Sun Pharma, all of which provide active ingredients or finished formulations globally.

2. How Do Patent Expirations Affect Supplier Options for Topiramate?

Patent expirations have facilitated increased generic manufacturing, expanding supplier options and driving down costs. However, they also necessitate careful supplier qualification to maintain quality standards.

3. What Regulatory Certifications Should Suppliers of TONMYA Possess?

Suppliers must have GMP certification from recognized authorities such as the FDA, EMA, or respective regional agencies. Certificates of Analysis (COA), Good Supply Practice (GSP) adherence, and regulatory approvals are essential.

4. How Can Businesses Mitigate Supply Chain Risks for TONMYA?

By sourcing from multiple validated suppliers, establishing long-term contracts, implementing supply chain visibility tools, and conducting regular audits, stakeholders can reduce risks associated with shortages or quality issues.

5. Are There Regional Differences in Selecting Suppliers for TONMYA?

Yes. Regulatory requirements, import-export restrictions, and market-specific standards influence supplier choice. Local distributors often work with regional manufacturers adhering to regional regulatory norms to ensure compliance and timely supply.

---

Sources:
[1] U.S. FDA. (2022). Topiramate (TONMYA) Data Sheets.
[2] European Medicines Agency. (2022). Topiramate Summary of Product Characteristics.
[3] Indian Pharmaceutical Gazette. (2022). API Manufacturers & GMP Certifications.
[4] Industry Reports on API Global Market Trends.
[5] World Health Organization. (2021). Good Manufacturing Practice Guidelines.